Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.60 |
| ▸ | TNF | P01375 | 7/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.51 |
| ▸ | HCK | P08631 | 2/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | MUSK | O15146 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092893 | 0.92 | MAPK14 (0.54) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4092399 | 0.92 | ABL1 (0.62) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4081253 | 0.84 | ABL1 (0.62) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4096809 | 0.84 | MAPK14 (0.65) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4095625 | 0.84 | SRC (0.56) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4092864 | 0.83 | ABL1 (0.73) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4094274 | 0.83 | MAPK14 (0.58) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4085378 | 0.82 | SRC (0.54) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4081491 | 0.81 | ABL1 (0.69) | MAPK14TNFABL1RAF1LYN | |
| SCHEMBL4092120 | 0.78 | MAPK14 (0.71) | MAPK14TNFABL1RAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026476-B2 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20030225077-A1 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225077-A1 | Intermediate arylamine compounds | AHR, AADAC, NAT1 | MAPK14 2681/4885TNF 257/4885ABL1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.